News | 28 April 2024
Apollo HealthCo to raise Rs. 2,475 crore from Advent International
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
New solvent-free micronization technology expanded at the Darmstadt site in Germany
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
The proposed facility is expected to be operational around January, 2027
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Sales reflect continued strong growth in oncology and vaccines
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Open a printable version of this pageEmail the URL of this page to a friend
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
Breakthrough Therapy designation for pain associated with DPN granted by FDA
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Subscribe To Our Newsletter & Stay Updated
